SkyAI, Inc. (NASDAQ: SKYAW)

Sharps Technology, Inc. is a medical device sales and distribution enterprise focused on the marketing and distribution of syringe products and related drug delivery systems. It also manages a digital asset treasury strategy centered on Solana (SOL) tokens. The company plans to expand its distribution platform by representing established third party manufacturers of complementary medical products serving a similar customer base. Sharps Technology, Inc. maintains compliance with applicable regulatory and quality standards, including those set by the U. S. Food and Drug Administration.

Revenue is generated primarily through sales of syringe products and related drug delivery systems to hospitals, clinics, healthcare providers, and medical supply organizations in domestic and international markets. Additionally, the company earns income from staking rewards and potential appreciation of its SOL holdings held in its treasury. The company may also generate proceeds from the sale of SOL to fund expansion plans.

Sharps Technology, Inc. operates within the medical device distribution industry with a focus on syringe and drug delivery products. The company emphasizes adherence to FDA and international regulatory standards as a core component of its business model. Its digital asset treasury strategy, which holds a significant position in Solana (SOL), provides additional financial resources that can support growth initiatives. No explicit competitors are disclosed in the filing.

The company serves hospitals, clinics, healthcare providers, and medical supply organizations located in both domestic and international markets. No specific customer names are disclosed in the filing.